Lantheus Inc. (LNTH)
Lantheus Inc. (LNTH) Stock Price, Analysis & Data
| Bid | 72.62 |
| Market Cap | 6.59B |
| Revenue (ttm) | 1.56B |
| Net Income (ttm) | 275.3M |
| Beta | -0.03 |
| EPS (ttm) | 4.18 |
| PE Ratio (ttm) | 24.15 |
| Forward PE | 16.03 |
| P/B (ttm) | 5.42 |
| P/S (ttm) | 4.23 |
| Earnings Date | Nov 5, 2026 |
| Ask | 129.74 |
| Volume | 1,299,906 |
| Avg. Volume (20D) | 1,309,606 |
| Open | 100.95 |
| Previous Close | 100.94 |
| Day's Range | 100.85 - 101.10 |
| 52-Week Range | 49.67 - 111.86 |
| Analyst | Buy |
| Price Target | 105 (4.01%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, a...
Financial Performance
In 2025, Lantheus's revenue was 1.54B, an increase of 0.5% compared to the previous year's 1.53B. Earnings were 233.56M, a decrease of -25.25%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for LNTH stock is "Buy". The 12-month stock price forecast is 105, which is upside of 4.01% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
